Evidence map›Paper›PMID 19440190›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2009

Paradoxical anxiogenic response of juvenile mice to fluoxetine.

Ji-eun Oh, Bojana Zupan, Steven Gross, Miklos Toth

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. 5-HTACS chemical neuroscience · 2021
    Article
  11. Serotonergic Facilitation of Forelimb Functional Recovery in Rats with Cervical Spinal Cord Injury.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Article
  12. Article
  13. Mouse model of the human serotonin transporter-linked polymorphic region.Mammalian genome : official journal of the International Mammalian Genome Society · 2019
    Article
  14. Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Article
  15. Loss of Adult 5-HT1A Autoreceptors Results in a Paradoxical Anxiogenic Response to Antidepressant Treatment.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ji-eun OhDepartment of Pharmacology, Weill Medical College of Cornell University, New York, NY 10021, USA.
Bojana Zupan
Steven Gross
Miklos Toth
Cornell University · US

Funding

NEUROBIOLOGY OF ANXIETY IN MICE LACKING 5HT 1A RECEPTORR01MH058669 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI TOTH, MIKLOS · 2000 to 2010
$3.1M
Long-term adverse effect of postnatal fluoxetine in miceR21MH072820 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI TOTH, MIKLOS · 2005 to 2006
$366k
NIMH NIH HHS 1R21MH072820NIMH NIH HHS 5R01MH058669NIMH NIH HHS R01 MH058669NIMH NIH HHS R21 MH072820
6 · The paper itself

Abstract

Depression, anxiety, and conduct disorders are common in children and adolescents, and selective serotonin reuptake inhibitors (SSRIs) are often used to treat these conditions. Fluoxetine (Prozac) is the first approved SSRI for the treatment of depression in this population. Although it is believed that overall, fluoxetine is effective in child and adolescent psychiatry, there have been reports of specific adverse drug effects, most prominently, suicidality and psychiatric symptoms such as agitation, worsening of depression, and anxiety. Chronic fluoxetine substantially increases brain extracellular 5-HT concentrations, and the juvenile developing brain may respond to supraphysiological 5-HT levels with specific adverse effects not seen or less prominent in adult brain. Using novelty-induced hypophagia, as well as open-field and elevated plus maze tests, we show that both Swiss Webster and C57Bl/6 mice, receiving fluoxetine in a clinically relevant dose and during their juvenile age corresponding to child-adolescent periods in humans, exhibit a paradoxical anxiogenic response. The adverse effects of juvenile fluoxetine disappeared upon drug discontinuation and no long-term behavioral consequences were apparent. No adverse effect to chronic fluoxetine was seen in adult mice and a dose-dependent anxiolytic effect developed. These data show that the age of the mice, independently of the strains and tests used in this study, is the determining factor of whether the response to chronic fluoxetine is anxiolytic or anxiogenic. Taken together, the response of the juvenile and adult brain to fluoxetine could be fundamentally different and the juvenile fluoxetine administration mouse model described here may help to identify the mechanism underlying this difference.

Indexed as

Age FactorsAnalysis of VarianceAnimalsAnimals, NewbornAnxietyBehavior, AnimalCell ProliferationDentate GyrusDisease Models, AnimalDose-Response Relationship, DrugDrinking BehaviorDrug Administration ScheduleExploratory BehaviorFluoxetineInfusion Pumps, ImplantableMaleFluoxetinenorfluoxetineSelective Serotonin Reuptake Inhibitors

Identifiers

PMID19440190
PMCPMC2771172
OpenAlexW2052697406

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.